In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori

scientific article

In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/AAC.44.7.1977-1979.2000
P8608Fatcat IDrelease_chsjltlzk5hrtpxqs4tnyclrdm
P932PMC publication ID89996
P698PubMed publication ID10858365

P2093author name stringA M Hirschl
M Wimmer
M L Rotter
A Makristathis
P Apfalter
P2860cites workIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agentsQ28379204
Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humansQ33976974
In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococciQ33977497
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 studyQ33978090
The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.Q34747691
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinonesQ35123200
In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus speciesQ35132865
Gastric diffusion of antibiotics used against Helicobacter pyloriQ41744415
Antibiotic resistance in Helicobacter pylori: implications for therapyQ50128865
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.Q53564053
Will Helicobacter pylori be the next organism for which we will have exhausted our treatment options?Q54098348
The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapiesQ61960641
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study GroupQ73634127
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsiaQ77716745
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectclarithromycinQ118551
metronidazoleQ169569
Helicobacter pyloriQ180556
amoxicillinQ201928
linezolidQ411377
P304page(s)1977-1979
P577publication date2000-07-01
P1433published inAntimicrobial Agents and ChemotherapyQ578004
P1476titleIn vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori
P478volume44

Reverse relations

cites work (P2860)
Q64243638In Vitro Activity of 3-Bromopyruvate, an Anticancer Compound, Against Antibiotic-Susceptible and Antibiotic-Resistant Strains
Q35014416In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms
Q46497875In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole
Q33183184Oxazolidinone antibiotics.
Q24530627Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors

Search more.